EMA Withdrawn: Opgenra (eptotermin alfa) — Olympus Biotech International Limited

View source ↗

Summary

EMA withdrew Opgenra (eptotermin alfa) from the market; previously indicated for spondylolisthesis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spondylolisthesis

Drugs mentioned

• Opgenra (eptotermin alfa)

Snippet

Status: Withdrawn. Therapeutic area: Spondylolisthesis. MAH: Olympus Biotech International Limited. Decision date: 01/07/2016